Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07614594 | Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis | recruiting | — | 800 | Henan Provincial People's HospitalOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07119996 | Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients | recruiting | Phase 1 | 12 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 30, 2026 |
| clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673016 | Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer(INSITE) | recruiting | — | 2,500 | Convergent Genomics, Inc.NETWORK | 2 | Jun 29, 2026 | clinicaltrials |
| NCT05312671 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | recruiting | Phase 2 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05204186 | Impact of COMORBIDities After Radical Cystectomy Using a Predictive Method With Artificial Intelligence(COMORBID-AI) | recruiting | — | 500 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06434350 | Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) | recruiting | Phase 1 / Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06630416 | Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors | recruiting | Phase 2 | 64 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646145 | Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 2 | 30 | Shanxi Province Cancer HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04106115 | DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr(DURANCE) | recruiting | Phase 1 / Phase 2 | 52 | University College, LondonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07029256 | Ultrasound-Guided Core Needle Biopsy to Stage Urothelial Carcinoma of the Bladder (US UCB) | recruiting | — | 100 | Mayo ClinicOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07524426 | Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment(LORUP) | recruiting | N/A | 248 | Umeå UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06421142 | FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer | recruiting | N/A | 80 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06388720 | The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy(IMGeS) | recruiting | Phase 2 | 82 | National Cancer Center, KoreaOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07475403 | Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07602010 | Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging | recruiting | — | 150 | Oslo University HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT07581496 | T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer | recruiting | — | 35 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06586255 | Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer | recruiting | Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07048496 | Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support(BCG at Home) | recruiting | N/A | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07087860 | Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers(RECIPE-B1) | recruiting | Phase 2 | 70 | Mayo ClinicOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06822010 | SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma | recruiting | Phase 2 | 28 | Rutgers, The State University of New JerseyOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06892860 | Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer(DISCUS) | recruiting | Phase 2 | 320 | Queen Mary University of LondonOTHER | 3 | May 6, 2026 | clinicaltrials |
| NCT06986304 | Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy(SR-ULM BC) | recruiting | — | 30 | Duke UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05646485 | Bladder Cancer Screening Trial | recruiting | N/A | 1,000 | University of Texas Southwestern Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07413523 | Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA(ASTRA) | recruiting | N/A | 44 | Istituto Clinico HumanitasOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04878029 | Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 1 | 32 | Emory UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05982561 | Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer | recruiting | — | 500 | Early is Good Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05562791 | A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07545694 | Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle | recruiting | — | 65 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07322263 | Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC | recruiting | Phase 2 | 174 | Michael A. O'DonnellOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07514143 | Bladder EpiCheck Product Development Study | recruiting | — | 1,000 | Nucleix Ltd.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514897 | Detecting CREPT in Urine for Bladder Cancer Diagnosis and Monitoring | recruiting | — | 250 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06704191 | In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial | recruiting | Phase 1 / Phase 2 | 40 | Mayo ClinicOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07420517 | Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer(DutaBCa-1) | recruiting | Phase 2 | 95 | Paul TorenOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06800963 | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG | recruiting | Phase 1 / Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495072 | Early vs Delayed Intravesical Blad-Care During BCG Therapy(PRO-GAG) | recruiting | N/A | 56 | BLAD-HYA GroupOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06447064 | Cancer Loyalty Card Study 2 (CLOCS-2)((CLOCS-2)) | recruiting | — | 2,900 | Imperial College LondonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492628 | Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma(DUET-UC-NK) | recruiting | Phase 1 | 42 | Beijing BiotechINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05037279 | Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)(EVER) | recruiting | Phase 3 | 540 | Verity Pharmaceuticals Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06721260 | Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)(METRICS) | recruiting | — | 30 | University of Kansas Medical CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04970472 | Bio Clinical Collection of Urothelial Carcinoma(MicroBlad) | recruiting | — | 1,000 | University Hospital, ToulouseOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05102110 | Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.(ORI-EGI-03) | recruiting | — | 450 | Origin SciencesINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06109857 | Bladder Bank (a Prospective Banking Study) | recruiting | — | 1,500 | Mayo ClinicOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07474519 | Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer | recruiting | Phase 4 | 40 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06173349 | PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer | recruiting | Phase 1 | 12 | University of California, DavisOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 2, 2026source: clinicaltrials